viewInstem PLC

Instem seeing all clients place orders as healthcare market stays buoyant

Phil Reason, chief executive of healthcare AI software group Instem PLC (LON:INS), says business was strong across all areas of the group in the first six months of 2019.

Even a change from licences to a SaaS or pay-as you-use model has gone smoothly, he says, with cash inflows strong over the first six months.

Healthcare generally is very strong and that drives more people to Instem, said Reason.

The SEND platform, which helps companies present data to the US FDA in a consistent format, saw revenues double for example, though Reason says all clients are placing orders.

Instem is looking at acquisitions, particularly in the area of software for later-stage clinical trials.

Quick facts: Instem PLC

Price: 520 GBX

Market: AIM
Market Cap: £106.51 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...



Instem PLC has 'significant capital' to accelerate acquisition strategy...

Instem PLC's (LON:INS) Phil Reason tells Proactive London's Andrew Scott he's pleased with its first-half trading. He says the number's were in line with forecasts and momentum has continued into the second half. Revenues for the six months ended June 30, 2020, were up 20%, or 12% on a...

2 weeks, 5 days ago

2 min read